Bio-Rad Q3 Revenues Rise 8 Percent as Profit Surges 43 Percent | GenomeWeb
NEW YORK (GenomeWeb News) — Bio-Rad Laboratories today said third-quarter revenues increased 8 percent as R&D spending rose 8 percent and profit increased 43 percent.
 
Total receipts for the three months ended Sept. 30 increased to $305 million from $283 million year over year.
 
Revenue from the company’s Life Science division was up 4 percent to $137 million from $132 million while receipts from the Clinical Diagnostics segment jumped 11 percent to $164 million from $148 million year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.